Unlocking Potential: Big Pharma Execs Embrace Biotech Opportunities
)
)
In recent years, we have seen a flurry of Big Pharma executives transition into Biotech CEO positions. The opportunity to work in a more agile and entrepreneurial environment, whilst driving a transformative mission centred around innovation and patient care, continues to prove an attraction. We are fortunate to see these qualities every day in many of the Biotechs we work alongside.
GSK’s Chief Scientific Officer, Hal Barron, announced last month that he will be stepping down and joining Altos Labs later this year. Altos Labs is an innovative Biotech start-up with $3B in funding and a focus on reversing disease and the ageing process. The movement of Big Pharma executive talent into early-stage Biotech is becoming a growing trend, and something that Venari Partners is closely associated with.
Our Director, Life Sciences & Healthcare, Ben Brickell, takes a look at what is attracting experienced leaders to jump from Big Pharma to Biotech.
Swipe to learn more about their move to Altos Labs, Galapagos, Eikon Therapeutics, Karyopharm Therapeutics Inc., AlloVir, Kite Pharma, Atara Biotherapeutics, Enzyvant, Forma Therapeutics
- Insight
- Market Update
- Leadership
)
Cristian joined Venari Partners in 2019 and specialises in executive search across digital health and healthtech. He works closely with emerging and high-growth businesses across the US and Europe, helping them build leadership teams to support their growth and commercial ambitions. His sector expertise spans SaaS, digital therapeutics, AI, virtual care, real-world evidence (RWE) and healthcare IT, with a focus on senior appointments across strategy, business development, operations and commercial functions. With extensive experience supporting healthtech companies through key stages of growth, Cristian advises on C-suite, VP and Director-level appointments, board recruitment and succession planning. He also provides specialist support with US go-to-market expansion for European businesses, alongside interim solutions, market mapping, compensation benchmarking and leadership and organisational assessments. Combining deep sector knowledge with an understanding of the challenges facing growing healthtech businesses, Cristian brings a considered approach to identifying leadership talent and supporting organisations through critical stages of development.
View Full Profile)
)
)
)
)
)
